AMG-510(Sotorasib)

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

可选规格

包装

价格

促销价

数量
5mg

￥1200.00

700.00

- +
10mg

￥2000.00

1200.00

- +
25mg

￥3000.00

2000.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

AMG-510 is a selective and orally bioavailable KRAS G12C covalent inhibitor.

货号：ajci75454

CAS：2296729-00-3
分子式：C30H30F2N6O3
分子量：560.59
纯度：98%
存储：Store at -20°C
库存：现货

Background:

AMG-510 is a selective and orally bioavailable KRAS G12C covalent inhibitor.

In vivo pharmacodynamic assays demonstrated dose- and time-dependent inhibition of KRASG12Csignaling in human pancreatic and NSCLC tumor xenografts. Covalent modification of KRASG12C by AMG 510 was measured by mass spectrometry and correlated with p-ERK inhibition in tumors. AMG 510 significantly inhibited the growth of KRAS p.G12C xenografts and resulted in tumor regression. Combination treatment of AMG 510 with standard-of-care and targeted agents demonstrated enhanced tumor growth inhibition compared to either single agent. In a syngeneic model of KRAS p.G12C mutant cancer, AMG 510 treatment significantly inhibited tumor growth and caused regression[1].

In cellular assays, AMG 510 covalently modified KRASG12C and inhibited KRASG12C signaling as measured by phosphorylation of ERK1/2 (p-ERK) in all KRAS p.G12C-mutant cell lines tested but did not inhibit p-ERK in cell lines with various other KRAS mutations. AMG 510 also selectively impaired viability of KRAS p.G12C mutant cell lines but did not affect cell lines with other KRAS mutations[1].

参考文献：

1. Karen Rex, et al. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Experimental and Molecular Therapeutics.

2. Marwan Fakih, et al, Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12Cinhibitor, in advanced solid tumors. Journal of Clinical Oncology.